Lester Leung: The Lancet Highlights TAPIS Trial at ESOC 2026
Lester Leung, Chief of Stroke and Cerebrovascular Diseases at Tufts Medical Center, shared The Lancet’s post on X about a recent article by Anxin Wang, published in The Lancet, adding։
”Challenges concerns about concurrent antiplatelet therapy with intravenous thrombolysis for acute ischemic stroke.”
The Lancet shared a post on X:
”Presented today at ESOC 2026:
Ticagrelor with aspirin dual antiplatelet therapy combined with intravenous thrombolysis in patients with ischaemic stroke in China (TAPIS): a multicentre, double-blind, randomised controlled trial.”
Title: Ticagrelor with aspirin dual antiplatelet therapy combined with intravenous thrombolysis in patients with ischaemic stroke in China (TAPIS): a multicentre, double-blind, randomised controlled trial
Authors: Anxin Wang, Xue Xia, Ying Tang, Fan Zhang, Xinsheng Han, Jing Li, Xiaoli Zhang, Jing Wang, Yulin Song, Fengyuan Che, Yuzhang Bei, Yong He, Wenji Jing, Junfang Hao, Jinzhao He, Hongqin Yang, Shu Chen, Wei Wu, Ying Li, Hongguo Dai, Chengyan Yang, Zengqiang Sun, Li Li, Yunchao Chen, Philip M Bath, Guillaume Turc, Yilong Wang
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 27, 2026, 18:19Nabil Tabish: The Paradox of Zero – Investigating Extreme VWF Discordance
-
Jun 27, 2026, 18:19Francesco Favruzzo: Can Mechanical Thrombectomy Be Safely Used in Cervical Artery Dissection?
-
Jun 27, 2026, 18:18Vera Ghali: 2026 ASH–ISTH Recommendations on Pediatric VTE Prevention
-
Jun 27, 2026, 18:17Michiel Coppens: A Hemostasis Laboratory – One of the Cornerstones of Our Hemophilia Mission
-
Jun 27, 2026, 18:16Sthanu Subramanian: Dabigatran and Mechanical Heart Valves
-
Jun 27, 2026, 15:50Muhammet Özbilen: The Skin as an Emerging Regulator of Iron Homeostasis
-
Jun 27, 2026, 15:07Anteneh Berhane: Supporting Healthier Pregnancies Through Early Nutrition
-
Jun 27, 2026, 14:35Mobina Nakhaei: Why Alloantibodies Develop Despite ABO/Rh Matching in Thalassemia
-
Jun 27, 2026, 14:01Abdul Mannan: DOACs in Cancer-Associated VTE – When to Avoid Them, And When LMWH Wins